MedTrace Logo

Evaluation of SmartSleep Technology for Improving the Efficiency and Restorative Quality of Sleep in Healthy Adults

NCT03911154 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-10-06

Study results available
· View outcomes & findings →

Summary

This study aims to assess whether slow wave sleep enhancement using SmartSleep technology benefits daytime cognitive performance during periods of chronic sleep restriction.

Conditions

  • Sleep

Interventions

DEVICE

Philips SmartSleep Technology--Continuous Fixed Interval modality

During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities: 1. Continuous Fixed Interval 2. Block 3. In-Phase Adjustable 4. Sham: No auditory stimulation while wearing the SmartSleep headband

DEVICE

Philips SmartSleep Technology--Block modality

During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities: 1. Continuous Fixed Interval 2. Block 3. In-Phase Adjustable 4. Sham: No auditory stimulation while wearing the SmartSleep headband

DEVICE

Philips SmartSleep Technology--In-Phase Adjustable modality

During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities: 1. Continuous Fixed Interval 2. Block 3. In-Phase Adjustable 4. Sham: No auditory stimulation while wearing the SmartSleep headband

Sponsors & Collaborators

  • National Aeronautics and Space Administration (NASA)

    collaborator FED

  • Philips Healthcare

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    collaborator OTHER

  • University of Pennsylvania

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-29
Primary Completion
2021-06-30
Completion
2021-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03911154 on ClinicalTrials.gov